авторефераты диссертаций БЕСПЛАТНАЯ БИБЛИОТЕКА РОССИИ



Pages:     | 1 |   ...   | 2 | 3 ||

«1 Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения Российской Федерации ...»

-- [ Страница 4 ] --

135. Kupperman E., Lee E.C., Cao Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010. 70(5): 1970–80.

136. Ladetto M., Magni M., Pagliano G., et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

Biol. Bl. Marr. Transplant. 2006. 12: 1270–76.

137. Lannutti J., Meadows S.A., Kashishian A., Steiner B., Puri K.D., Giese N.A.

Cal-101, a specific inhibitor of the P110delta isoform of phosphatidylinositide 3-kinase, for the treatment of non-Hodgkins lymphomas. Haematologica. 2009. 94: 272–73.

138. Lefrere F., Delmer A., Levy V., et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma:

an update of a prospective study. Haematologica. 2004. 89: 1275–76.

139. Le Gouill S., Callanan M., Macintyre E., et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa Study. Blood 2012 (ASH Annual Meeting Abstracts), Vol. 120(21): Abstract #152.

140. Lennert K. Malignant Lymphomas other than Hodgkin’s disease. New York:

Springer-Verlag. 1978.

141. Lennert K., Stein H., Kaiserling E. Cytological and functional criteria for the classification of malignant lymphoma Br. J. Cancer. 1975;

Suppl. 2: 29-43.

142. Lenz G., Dreyling M., Hoster et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 2005. Vol. 23:


143. Leonard J.P., LaCasce A., Smith M.R., et al. Cdk4/6 inhibitor PD demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2008.

112(11): Abstract #264.

144. Li J.Y., Gaillard F., Moreau A., et al. Detection of translocation t(11;


q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am. J.

Pathol. 1999. Vol. 154, 1449–52.

145. Liang M., Han X., Vadhan-Raj S., et al. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod. Pathol. 2010.

23(3): 381–91.

146. Licci S., Morelli L., Covello R., et al. Primary mantle cell lymphoma of the testis. Ann. Hematol. 2011. 90(4): 434–44.

147. Lin T.S., Ruppert A.S., Johnson A.J., et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J. Clin. Oncol. 2009. 27(35): 6012–18.

148. Liu Z., Dong H.Y., Gorczyca W., et al. CD5- mantle cell lymphoma. American Journal of Clinical Pathology. 2002. 118(2): 216–24.

149. Lopez A., Gutierrez A., Palacios A., et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur. J. Haematol. 2008. 80(2): 127–32.

150. Macintyre E.A., Belanger C., Debert C., Canioni D., Turhan A.G., et al.

Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Blood. 1995. 86: 4691–98.

151. Magni M., Di Nicola M., Carlo-Stella C., et al. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplantation.

2009. 43, 509– 152. Martinez N., Camacho F.I., Algara P., et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003. 63(23):


153. Marzec M., Kasprzycka M., Lai R., et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006. 108(5):1744–50.

154. McKay P., Leach M., Jackson R., Cook G., Rule S. Guidelines for the Investigation and Management of Mantle Cell Lymphoma. British Journal of Haematology. 2012. 159(4): 405–26.

155. Merli F., Luminari S., Ilariucci F., et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicenter trial from Gruppo Italiano Studio Linfoni. Br.

J. Haematol. 2012. 156(3): 346–53.

156. Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2007.

109(1): 271–80.

157. Miura I., Kobayashi Y., Takahashi N., Saitoh K., Miura A.B. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. Br. J. Haematol. 2000. 110(4): 876–79.

158. Morschhauser F., Seymour J.F., Kluin-Nelemans H.C., et al. Aphase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol. 2008. 19(2): 247–53.

159. Moskowitz C.H., Bertino J.R., Glassman J.R., et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J.

Clin. Oncol. 1999. 17(12): 3776–85.

160. Mozos A., Royo A., Hartmann E., et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclinD1-negative subtype. Haematologica.

2009. 94(11): 1555– 161. Mller J.R., Janz S., Goedert J.J., Potter M., Rabkin C.S. Persistence of immunoglobulin heavy chain/c-Myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual Men. Proc. Natl. Acad.

Sci. USA. 1995. 92(14): 6577–81.

162. Nambiar M. & Raghavan S.C. Prevalence and analysis of t(14;

18) and t(11;

14) chromosomal translocations in healthy Indian population. Ann. Hematol. 2010. 89(1):


163. Naranji I., Zakri R.H., Liston T. Mantle cell lymphoma presenting as a pelvi ureteric junction obstruction: a case report. J. Med. Case Rep. 2013. 16;

7(1): 105.

164. Naushad H., Choi W.W., Page C.J., Sanger W.G., Weisenburger D.D., Aoun P. Mantle cell lymphoma with flow cytometric evidence of clonal plasmacytic differentiation: a case report. Cytometry B. Clin. Cytom. 2009. 76(3): 218–24.

165. Ng M., Waters J., Cunningham D., Chau I., Horwich A., et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br. J. Cancer. 2005. 92: 1352–57.

166. Norton A.J., Matthews J., Pappa V., et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over 20-year period. Ann. Oncol. 1995.

vol. 6, p. 249–56.

167. Novak P.M., Mattson J.C., Crisan D., et al. Separate clones in concomitant multiple myeloma and a second B-cell neoplasm demonstrated by molecular and immynophenotypic analysis. Eur. J. Haematol. 1995. 54(4): 254–61.

168. O’Connor O.A. Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways. Hematology. Am. Soc. Hematol. Ed. Program. 2007. 270– 76.

169. O’Connor O.A., Moskowitz C., Portlock C., et al. Patients with chemotherapy refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br.

J. Haematol. 2009. 145(1): 34–39.

170. O’Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br.

J. Haematol. 2009. 145(1): 34–39.

171. O’Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR 171) in patients with hematologic malignancies. Clin. Cancer Res. 2009. 15(22): 7085– 91.

172. Oki Y., McLaughlin P., Pro B., Hagemeister F.B., Bleyer A., et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.

Cancer. 2005. 104(4): 781– 173. Orchard J., Garand R., Davis Z., et al. A subset of t(11;

14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, non-nodal disease. Blood. 2003. 101(12): 4975–81.

174. Ott G., Kalla J., Ott M.M., et. al. (1997) Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 1997. 89: 1421–29.

175. Paoluzzi L., Gonen M., Bhagat G., et al. The BH3-only mimetic ABT- synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Blood. 2008. 112(7): 2906–16.

176. Paoluzzi L., Gonen M., Gardner J.R., et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in vitro and in vivo models of B-cell lymphoma. Blood. 2008.

111(11): 5350–58.

177. Park B.B., Kim W.S., Eom H.S., et al. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Invest New Drugs 2011;


178. Prez-Galn P., Dreyling M., and Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011. 117:


179. Perez-Galan P., Mora-Jensen H., Weniger M.A., et al. Bortezomib resistance in mantle cell lymphoma is associated with expression of a plasmacytoid differentiation program. Blood. 2010. Blood. 2011. 117(2): 542–52.

180. Perez-Galan P., Roue G., Villamor N., Campo E., Colomer D. The BH3 mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 2007. 109(10): 4441–49.

181. Peterlin P., Leux C., Gastinne T., et al. Autologous stem cell transplantation in mantle cell lymphoma: total body irradiation (TBI) plus cyclophosphamide (or melphalan) is not superior to BEAM, A single institution experience.

Transplantation. 2012. 94(3): 295–301.

182. Philip T., Guglielmi C., Hagenbeek A., et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995. 333: 1540–45.

183. Pileri S., Rivano M.T., Gobbi M., Taruscio D., Lennert K. (1985) Neoplastic and reactive follicles within B-cell malignant lymphomas. a morphologic, immunological study of 30 cases. Hematol. Oncol. 1985. 3: 243–60.

184. Pinyol M., Bea S., Pla L., et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsensemediated mRNA decay pathway inhibition and microarray analysis.

Blood. 2007.109(12): 5422–29.

185. Pinyol M., Campo E., Nadal A., et al. Detection of the Bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. Am. J. Clin. Pathol. 1996. 105: 532–537.

186. Pinyol M., Hernandez L., Cazorla M. et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997. 89: 272–80.

187. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V.

Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol.

1995. 22 (4 Suppl 11): 3–10.

188. Pontano L.L., Diehl J.A. Speeding through cell cycle roadblocks: nuclear cyclin D1-dependent kinase and neoplastic transformation. Cell Div. 2008. 3:12.

189. Pott C., Hoster E., Beldjord K et al. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network. Blood. 2010. (ASH Annual Meeting Abstracts), 116: Abst. 965.

190. Prasad A., Park I.W., Allen H., et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene. 2009. 28(12): 1518– 28.

191. Psyrri A., Papageorgiou S., Liakata E., et al. Phosphatidylinositol3’-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin. Cancer Res. 2009. 15(18): 5724–32.

192. Racke F., Simpson S., Christian B., et al. Evidence of long latency periods prior to development of mantle cell lymphoma. Blood. 2010. 116: 323.

193. Raty R., Franssila K., Jansson S-E., et al. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. Eur. J. Cancer. 2003. 39:


194. Raymond E., Faivre S., Chaney S., Woynarowski J., Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 2002. 1(3): 227–35.

195. Reeder C.B., Gornet M.K., Habermann T.M., et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL) [abstract]. Blood.2007. 110(11): Abstract #121.

196. Rinaldi A., Kwee I., Taborelli M., et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 2006. 132(3): 303–16.

197. Rizzatti E.G., Falcao R.P., Panepucci R.A., et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br. J. Haematol. 2005. 130(4): 516–26.

198. Rodriguez J, Gutierrez A, Obrador-Hevia A, et al. Therapeutic concepts in mantle cell lymphoma. Eur. J. Haematol. 2010. 85(5): 371–86.

199. Rodriguez J., Gutierrez A., Palacios A. et al. Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk. Lymphoma 2007. 48: 2172–78.

200. Rodriguez-Monge E.J., Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol.

Oncol. Clin. North Am. 1997. 11(5): 937–47.

201. Romaguera J.E., Khouri I.F., Kantarjian H.M., et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk. Lymphoma. 2000. 39: 77–85.

202. Romaguera J.E., Medeiros L.J., Hagemeister F.B., et al. Frequency of gastrointestinal involvement and its clinical signicance in mantle cell lymphoma.

Cancer 2003. 97: 586–91.

203. Romaguera J.E., Fayad L., Feng L., et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br. J. Haematol. 2010. 150(2): 200–08.

204. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High-rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 2005. 23: 7013–23.

205. Rosenwald A., Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003. 3(2): 185–97.

206. Rubio M., Boumendil A., Luan J. J., Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the lymphoma working party of the EBMT Abstracts.

207. Rudelius M., Pittaluga S., Nishizuka S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006.

108(5): 1668–76.

208. Rummel M.J., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Phase 3 non inferiority Trial. Lancet. 2013. 381(9873): 1203–10.

209. Salar A., Juanpere N., Bellosillo B., et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic and pathologic study. Am. J.

Surg. Pathol. 2006. 30: 1274–80.

210. Sander S., Bullinger L, Leupolt E, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Haematologica. 2008. 93(5): 680–87.

211. Seyfarth B., Josting A., Dreyling M., Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br. J. Haematol. 2006. 133(1): 3–18.

212. Schaffel R., Hedvat C.V., Teruya-Feldstein J., et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma Annals of Oncology 2010. 21:


213. Schaffner C., Idler I., Stilgenbauer S., Dohner H., Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc. Natl. Acad. Sci. USA.

2000. 97: 2773–78.

214. Schenk T.M., Keyhani A., Bottcher S., et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 1998. 12(5):


215. Smithers D.W. Summary of papers delivered at the Conference on Staging in Hodgkin's Disease (Ann Arbor). Cancer Res. 1971. 31(11): 1869–70.

216. Smock K.J., Yaish H.M., Cairo M.S., et al. Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature. Pediatr. Dev. Pathol., 2007. 10(5): 430–38.

217. Sriganeshan V., Blom T., Weissmann D. A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+ immunophenotype and typical morphology Arch. Pathol. Lab. Med. 2008. 132(8): 1346–49.

218. Stewart D.A., Vose J.M., Weisenberger D.D., et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann. Oncol. 1995. 6: 263–66.

219. Soiffer R.J., Caligiuri M.A., Tondini C., Canellos G.P. High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin’s lymphoma. Limited role as a single agent. Cancer. 1989. 64(10): 2014–18.

220. Stocklein H., Hutter G., Kalla J., et al. Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma. J.

Hematop. 2008. 1(2): 85–95.

221. Sun T., Nordberg M., Cotelingam J., et al. Fluorescence in situ hybridization:

method of choice for a definitive diagnosis of mantle cell lymphoma. American Journal of Hematology. 2003. 74(1): 78–84.

222. Swerdlow S.H., Campo E., Harris N.L. et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 2008. Lyon: IARC.

223. Takahashi N., Miura I., Saitoh K. and Miura A.B. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood. 1998. 92: 4758–63.

224. Tam C., Bassett R., Ledesma C., et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood.

2009. 113(18): 4144–52.

225. Tam C.S. and Khouri I.F. Autologous and allogeneic stem cell transplantation:

rising therapeutic promise for mantle cell lymphoma. Leukemia and Lymphoma. 2009.

50(8): 1239–48.

226. Thelander E.F., Rosenquist R. Molecular genetic characterization reveals new subsets of mantle cell lymphoma. Leuk. Lymphoma. 2008. 49(6): 1042–49.

227. Thieblemont C., Coiffer B. Lymphoma in older patients. J. Clin. Oncol. 2007.

25(14): 1916– 228. Tiemann M., Schrader C., Klapper W. et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br. J. Haematol. 2005.

131(1): 29–38.

229. Tort F., Camacho E., Bosch F., et al. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haemotologica 2004. 89: 314–19.

230. Valdez R., Kroft S.H., Ross C.W., et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod. Pathol. 2002. 15(10): 1073–79.

231. Van Den Berghe H., Parloir C., David G., et al. A new characteristic karyotypic anomaly in lymphoproliferative disorders. Cancer. 1979. 44: 188.

232. Van’t Veer M.B., de Jong D., MacKenzie M. et al. High-dose Ara-C and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br.

J. Haematol. 2009. 144(4): 524–30.

233. Vater I., Wagner F., Kreuz M., et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br. J. Haematol. 2009. 144(3): 317– 31.

234. Vegliante M.C., Palomero J., Prez-Galn P., et al. SOX11 regulates PAX expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013. 121(12): 2175–85.

235. Vigouroux S., Gaillard F., Moreau P., Harousseau J.L., Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica. 2005. 90(11): 1580–82.

236. Visco C., Finotto S., Zambello R., et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J. Clin. Oncol. 2013.

31(11): 1442–49.

237. Vose J.M. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 2012. 87(6): 604–09.

238. Voso M.T., Hohaus S., Moos M. and Haas R. Lack of t(14;

18) Polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. Blood. 1997. 89: 3763–68.

239. Wang M., Rule S.A., Martin P., et al. Interim results of an international, multicenter, phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI 32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. ASH 54th Annual Meeting. 2012. Vol.: 120, Issue 21.

Abstract #904.

240. Walsh S.H., Thorselius M., Johnson A., et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood. 2003.

101(10): 4047–54.

241. Wartenberg M., Vasil P., Bueschenfelde C.M., et al. Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse.

Haematologica 2013. 98(9): 1433–41.

242. Weisenburger D.D., Kim H., Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer. 1982. 49(7): 1429–38.

243. Weisenburger D.D., Vose J.M., Greiner T.C., et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am. J.

Hematol. 2000. Vol. 64, p. 190–96.

244. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979 (Offset publication №48).

245. Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007. 109(11): 4599–06.

246. Williams M.E., Whitefield M., Swerdlow S.H. Analysis of the cyclin dependent kinase inhibitirs p18 and p19 in mantle cell lymphoma and chronic lymphocytic leukemia. Ann. Oncol. 1997. 8 Suppl. 2: 71–73.

247. Williams M.E., Woytowitz D., Finkelstein S.D., Swerdlow S.H. MTS1/MTS (p15/p16) deletions and p53 mutations in mantle cell (centrocytic) lymphoma. Blood.

1995. 86: 747a–50.

248. Wilson W.H., Dunleavy K., Pittaluga S., et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J. Clin. Oncol. 2008. Vol. 26:


249. Wilson W.H., Grossbard M.L., Pittaluga S., et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood. 2002. 99: 2685–93.

250. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 2005. 23(23):


251. Witzig T.E., Geyer S.M., Kurtin P.J., et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk. Lymphoma 2008. 49(6): 1074–80.

252. Witzig T.E., Vose J.M., Zinzani P.L., Reeder A., Buckstein R. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin’s lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003). Blood. (ASH Annual Meeting Abstracts) 2009. 114(22):

Abstract #1676.

253. Wlodarska I., Meeus P., Stul M., et al. Variant t(2;


q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B non-Hodgkin lymphoma. Leukemia. 2004;

18: 1705–10.

254. Woehrer S., Hejna M., Skrabs C., et al. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology. 2005;


255. Yarkoni S., Lishner M., Tangi I., Nagler A., Lorberboum-Galski H. B-Cell Non-Hodgkin's Lymphoma: Evidence for the t(14;

18) translocation in all hematopoietic cell lineages. Journal of the National Cancer Institute. 1996. 17;

88(14): 973–79.

256. Yatabe Y., Suzuki R., Matsuno Y., et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: Study of 168 cases. Pathology International. 2001.

Vol. 51, p. 747–61.

257. Yatabe Y., Suzuki R., Tobinai K., et al. Significance of cyclin D overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000. 95: 2253–61.

258. Yee K.W., Zeng Z., Konopleva M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2006. 12(17): 5165–73.

259. Yin C.C. and Luthra R. Molecular Detection of t(11;


q32) in mantle cell lymphoma. Methods in Molecular Biology 2013. Vol. 999: 211–16.

260. Younes A. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma:

clues but no clear answers. Autophagy. 2008. 4(5): 707–09.

261. Young K.H., Chan W.C., Fu K., et al. Mantle cell lymphoma with plasma cell differentiation. Am. J. Surg. Pathol. 2006. 30(8): 954–61.

262. Zapata M., Budnick S., Bordoni R., Li S. An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. Int. J. Clin.

Exp. Pathol. 2010. Mar 20;

3(4): 430–36.

263. Zattra E., Zambello R., Marino F., et al. Primary cutaneous mantle cell lymphoma. Acta. Derm. Venereol. 2011. 91(4): 474–75.

264. Zhao J.J., Lin J., Lwin T., et al. MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010. 115(13): 2630–39.

265. Zhou Y., Wang H., Fang W., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008. 113: 791–98.

266. Zinzani P.L., Tani M., Molinari A.L., et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica. 2002. 87(8): 816–21.

Pages:     | 1 |   ...   | 2 | 3 ||

© 2013 www.libed.ru - «Бесплатная библиотека научно-практических конференций»

Материалы этого сайта размещены для ознакомления, все права принадлежат их авторам.
Если Вы не согласны с тем, что Ваш материал размещён на этом сайте, пожалуйста, напишите нам, мы в течении 1-2 рабочих дней удалим его.